Question 65

Atomoxetine is at risk of being confused with the generic name for Strattera.

The generic name for Strattera, which is atomoxetine, is noted to have a potential for confusion, highlighting the importance of clear communication in medication naming.

A) Atomoxetine

This option is correct as atomoxetine is indeed the generic name for Strattera. The Institute for Safe Medication Practices (ISMP) points out that confusion can arise from the similarity in names, which is critical for safe prescribing and dispensing practices.

B) dapagliflozin

Dapagliflozin is an antidiabetic medication and does not share any direct name similarities with Strattera or its generic name, atomoxetine. Therefore, this option is incorrect as it does not relate to the risk of confusion highlighted by ISMP.

C) rivaroxaban

Rivaroxaban is an anticoagulant and, like dapagliflozin, does not have any name similarity with atomoxetine. This makes it an incorrect choice regarding the potential for name confusion with Strattera.

D) famotidine

Famotidine is a medication used to treat stomach ulcers and does not resemble the name atomoxetine. Consequently, this option is also incorrect, as it does not present a risk for confusion with Strattera.

Conclusion

Atomoxetine is the only option that accurately reflects the generic name for Strattera and is identified by ISMP as being at risk of confusion. The other choices do not share any name similarities that could lead to the same level of confusion, thereby confirming that option A is the only correct response in this context.